IL10 and T-cell non-Hodgkin lymphoma: Mechanistically, KCa3.1 activators suppress IL-10 transcription in T-cell lymphoma cells and attenuate IL-10-mediated immune evasion by reducing TAM-derived IL-10 production [268,269].